Larix laricina, an Antidiabetic Alternative Treatment from the Cree of Northern Quebec Pharmacopoeia, Decreases Glycemia and Improves Insulin Sensitivity In Vivo

Table 3

Effects of HFD and L. laricina administration on organ weights at sacrifice.

	Prevention protocol			Treatment protocol
	DIO	L. laricina	L. laricina	DIO	L. laricina	L. laricina
		125 mg/kg	250 mg/kg		125 mg/kg	250 mg/kg
Retroperitoneal fat pad (g)	1.34±0.05	1.26±0.04	1.14±0.05^∗	1.51±0.08	1.35±0.24	1.44±0.04
Epididymal fat pad (g)	2.40±1.00	2.56±0.08	2.56±0.07	1.21±0.03	1.32±0.18	1.85±0.12^∗
Brown fat pad (g)	0.30±0.03	0.33±0.01	0.28±0.02	0.44±0.01	0.37±0.06	0.42±0.02
Liver weight (g)	1.77±0.09	1.85±0.05	1.80±0.07	2.62±0.15	2.44±0.38	2.57±0.12
Liver index	410±2	429±1	437±1	551±3	539±5	555±2

Measurements were obtained after 8 weeks (prevention) or 16 weeks (treatment) of administration with either HFD (DIO) or L. laricina at 125 or 250 mg/kg, which was incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. The liver index corresponds to liver weight (mg)/body weight (mg). All values represent the mean ± SEM (prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8). ^*denotes that treated groups are significantly different as compared to DIO (one-way ANOVA; post hoc analysis Holm-Sidak or Bonferroni-Dunn test; 𝑃<0.05).